The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

NCT02588404 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2024-12-10

No results posted yet for this study

Summary

The objective of this study is to evaluate the predictive value of TMPRSS2-ERG gene fusion in patients with prostate cancer treated with radiation and hormonal therapy.

Conditions

Interventions

DRUG

LHRH therapy

These patients will be treated with LHRH agonist as standard therapy.

Sponsors & Collaborators

  • Sir Mortimer B. Davis - Jewish General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2030-01-31
Completion
2030-01-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02588404 on ClinicalTrials.gov